Montelukast vs Tofacitinib
Montelukast vs Tofacitinib: Overview
This comparison examines the pharmacological differences between Montelukast and Tofacitinib.
Mechanism of Action
Montelukast: Selective leukotriene D4 receptor antagonist.
Tofacitinib: Pan-JAK inhibitor with preference for JAK1 and JAK3 blocking pro-inflammatory cytokine signaling.
Pharmacokinetics
Half-life: Montelukast — 2.7-5.5 hours; Tofacitinib — 3.2 hours.
Chemical Properties
Molecular Formula: Montelukast — C35H36ClNO3S; Tofacitinib — C16H20N6O.
Molecular Weight: Montelukast — 586.1800 g/mol; Tofacitinib — 312.3700 g/mol.
Type: Montelukast — Small molecule; Tofacitinib — Small molecule.